refID;FullReference;groupID;country;diseaseStatus;year;agent;agentSubtypeType;agentDetails;targetSpecies;ageDC1;ageMonths;sampStrategy;sampUnit;sampUnitSize;route;testSubstanceCAT;dosageFreq;dosageInterval;dose;doseUnits;dayDose1;dayDose2;challengeType;challengeSubstance;challengeDose;challengeDoseUnits;challengeDay;lastVaccine;timePoint;experimentStatus;labTest;labDescription;labTarget;matrix;nTested;nPositive;testValue;testValueUnits;scaleMin;ScaleMax;deadUnits;mortalityTime;mortalityTimeUnits;efficacy;UCI_efficacy;LCI_efficacy;rowID;uniqueID;interventionType;dayDose1Std;dayDose2Std;challengeDayStd;timePointStd;experimentStatus2;ShortBibliography;Author;Title;Abstract;publicationYear
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;47;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;39;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;1;86251;vaccine;-21;NA;0;5;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;49;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;39.5;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;2;86251;vaccine;-21;NA;0;7;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;51;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;39.5;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;3;86251;vaccine;-21;NA;0;9;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;54;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;40;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;4;86251;vaccine;-21;NA;0;12;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;40;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;5;86251;vaccine;-21;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);5;4;0.6;titer;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;6;86251;vaccine;-21;NA;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);5;5;1.68;titer;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;7;86251;vaccine;-21;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;0;1st vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;0;109;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;8;86251;vaccine;-21;NA;0;-42;Not vaccinated/Before vaccination; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;21;2nd vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;0;117;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;9;86251;vaccine;-21;NA;0;-21;Vaccinated, not challenged; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;28;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;1;48;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;10;86251;vaccine;-21;NA;0;-14;Vaccinated, not challenged; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;1;55;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;11;86251;vaccine;-21;NA;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;5;7.2;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;12;86251;vaccine;-21;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Clinical evaluation;clinical signs observed for 15 days, on a scale that could go from 0 to 23 in any given day. Maximum reported score for any given animal in the experiment = 65;not investigated/not given/not relevant;live animal - clinical observation;5;NA;5.2;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;13;86251;vaccine;-21;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;1;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;21;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;40;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;14;86251;vaccine;-21;NA;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);5;0;0;titer;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;15;86252;vaccine;-42;-21;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);5;4;2.4;titer;NA;NA;1;51;days;NA;NA;NA;16;86252;vaccine;-42;-21;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;0;1st vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;0;109;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;17;86252;vaccine;-42;-21;0;-42;Not vaccinated/Before vaccination; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;21;2nd vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;4;17.6;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;18;86252;vaccine;-42;-21;0;-21;Vaccinated, not challenged; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;5;6.6;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;19;86252;vaccine;-42;-21;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;28;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;5;11;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;20;86252;vaccine;-42;-21;0;-14;Vaccinated, not challenged; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);4;4;4;IP;NA;NA;1;51;days;NA;NA;NA;21;86252;vaccine;-42;-21;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Clinical evaluation;clinical signs observed for 15 days, on a scale that could go from 0 to 23 in any given day. Maximum reported score for any given animal in the experiment = 65;not investigated/not given/not relevant;live animal - clinical observation;5;NA;31.2;Clinical score;0;0;1;51;days;NA;NA;NA;22;86252;vaccine;-42;-21;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;40;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;23;86252;vaccine;-42;-21;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;47;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;31;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;24;86252;vaccine;-42;-21;0;5;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;51;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;26;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;25;86252;vaccine;-42;-21;0;9;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;49;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;24;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;26;86252;vaccine;-42;-21;0;7;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;54;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;28;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;27;86252;vaccine;-42;-21;0;12;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;2;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;5;SUBCUTANEOUS;BTV-BTVPUR AlSap 2-4;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;30;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;28;86252;vaccine;-42;-21;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;NA;42;Challenge day;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);6;0;0;titer;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;29;86253;control;NA;NA;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;NA;56;After challenge;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);5;5;2.1;titer;NA;NA;1;51;days;NA;NA;NA;30;86253;control;NA;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;0;1st vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);6;0;104.8;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;31;86253;control;NA;NA;0;-42;Not vaccinated/Before vaccination; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;21;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);6;0;100.5;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;32;86253;control;NA;NA;0;-21;Not vaccinated/Before vaccination; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;28;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);6;0;95;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;33;86253;control;NA;NA;0;-14;Not vaccinated/Before vaccination; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);6;0;100.2;IP;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;34;86253;control;NA;NA;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);5;5;8.8;IP;NA;NA;1;51;days;NA;NA;NA;35;86253;control;NA;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Clinical evaluation;clinical signs observed for 15 days, on a scale that could go from 0 to 23 in any given day. Maximum reported score for any given animal in the experiment = 65;not investigated/not given/not relevant;live animal - clinical observation;5;NA;37.2;Clinical score;0;0;1;51;days;NA;NA;NA;36;86253;control;NA;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;42;Challenge day;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;6;NA;40;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;37;86253;control;NA;NA;0;0;Challenge day; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;47;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;6;NA;28;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;38;86253;control;NA;NA;0;5;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;49;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;6;NA;27.5;Cq/Ct;NA;NA;0;NA;not investigated/not given/not relevant;NA;NA;NA;39;86253;control;NA;NA;0;7;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;51;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;27;Cq/Ct;NA;NA;1;51;days;NA;NA;NA;40;86253;control;NA;NA;0;9;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;54;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;30;Cq/Ct;NA;NA;1;51;days;NA;NA;NA;41;86253;control;NA;NA;0;12;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8625; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara (2015).  Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines Vaccine, 33(#issue#),  512-518;3;France;not investigated/not given/not relevant;2013;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;6;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;millilitre;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;3;milliliter;42;21;56;After challenge;Reverse-transcription PCR (RT-PCR);NucleoSpin RNA Virus Kit;Nucleic acid;Animal blood;5;NA;30;Cq/Ct;NA;NA;1;51;days;NA;NA;NA;42;86253;control;NA;NA;0;14;After challenge; Emmanuel Breard, et al. 2015.; Emmanuel Breard, Guillaume Belbis, Cyril Viarouge, Kyriaki Nomikou, Andy Haegeman, Kris De Clercq, Pascal Hudelet, Claude Hamers, Francis Moreau, Thomas Lilin, Benoit Durand, Peter Mertens, Damien Vitour, Corinne Sailleau, Stephan Zientara;Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines;Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination. (C) 2014 Elsevier Ltd. All rights reserved.;2015
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;Clinical evaluation;number of animals ever showing pyrexia during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;2;20;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;43;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;Clinical evaluation;number of animals ever showing head tremors or muscle fasciculations during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;2;20;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;44;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;Clinical evaluation;number of animals ever showing mild paresis during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;2;20;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;45;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;Clinical evaluation;number of animals ever showing depression or anxiety during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;6;60;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;46;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;56;After challenge;Virus Isolation (VI);all sera collected from challenged animals were tritrated using a standard double overlay plaque assa of Vero cells.  All sera were tested undiluted in duplicate by inoculating 0.1ml aliquot per well in six-well plates. samples were collected to quantify viremia immediately prior to challenge (day42), twice daily on days 43-49 and once daily on days 50-56.  Results given are for number of horses ever showing viremia during the 14 days post-challenge;Virus;Blood serum (as part-nature);10;1;10;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;47;86451;vaccine;-42;-21;0;14;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;Clinical evaluation;number of animals ever showing head tremors or muscle fasciculations during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;10;100;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;48;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;Clinical evaluation;number of animals ever showing mild paresis during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;9;90;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;49;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;Clinical evaluation;number of animals ever showing depression or anxiety during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;10;100;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;50;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;56;After challenge;Virus Isolation (VI);all sera collected from challenged animals were tritrated using a standard double overlay plaque assa of Vero cells.  All sera were tested undiluted in duplicate by inoculating 0.1ml aliquot per well in six-well plates. samples were collected to quantify viremia immediately prior to challenge (day42), twice daily on days 43-49 and once daily on days 50-56.  Results given are for number of horses ever showing viremia during the 14 days post-challenge;Virus;Blood serum (as part-nature);10;8;80;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;51;86452;control;NA;NA;0;14;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 0 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;9;90;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;52;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 1 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;1;10;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;53;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 2 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;54;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 3 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;55;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 4 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;56;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 5 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;57;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 4 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;58;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 3 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;59;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 1 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;60;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 2 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;61;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 0 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;10;100;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;62;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 5 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;63;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 4 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;64;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 3 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;65;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 2 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;66;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 1 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;1;10;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;67;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 5 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;68;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;1;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;INTRAMUSCULAR;WNV-Equip WNV (previously Duvaxyn WNV);2;21;NA;not investigated/not given/not relevant;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;21;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 0 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;90;900;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;69;86451;vaccine;-42;-21;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 0 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;70;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 1 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;71;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 2 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;4;40;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;72;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 3 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;1;10;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;73;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 4 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;74;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 5 in pons region;not investigated/not given/not relevant;Brain (as part-nature);10;5;50;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;75;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 0 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;76;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 1 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;77;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 2 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;4;40;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;78;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 3 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;1;10;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;79;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 4 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;1;10;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;80;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 5 in medulla region;not investigated/not given/not relevant;Brain (as part-nature);10;4;40;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;81;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 0 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;82;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 1 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;0;0;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;83;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 2 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;5;50;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;84;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 3 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;2;20;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;85;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 4 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;2;20;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;86;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;not investigated/not given/not relevant;Histopathologic evaluation of hematoxylin and eosin stained sections of brain stem were evaluated and scored by a veterinary pathologist and scored between 0 (no apparent lesions) and 5 (very severe and extensive lesions).  Number with severity score 5 in anterior cord region;not investigated/not given/not relevant;Brain (as part-nature);10;1;10;% POS, not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;87;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8645; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons (2014).  Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine Vaccine, 32(#issue#),  5455-5459;2;United States;Endemic;NA;West Nile virus;not investigated/not given/not relevant;not investigated/not given/not relevant;Horse (Equus ferus caballus);not investigated/not given/not relevant;NA;Objective (random) sampling;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;1;milliliter;42;NA;63;After challenge;Clinical evaluation;number of animals ever showing pyrexia during 21 days post-challenge;not investigated/not given/not relevant;live animal - clinical observation;10;10;100;% POS, Clinical evaluation;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;88;86452;control;NA;NA;0;21;After challenge; Bowen RichardA, et al. 2014.; Richard A. Bowen, Angela Bosco-Lauth, Kevin Syvrud, Anne Thomas, Todd R. Meinert, Deborah R. Ludlow, Corey Cook, Jeremy Salt, Ellen Ons;Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine;Over the last years West Nile virus (WNV) lineage 2 has spread from the African to the European continent. This study was conducted to demonstrate efficacy of an inactivated, lineage 1-based, WNV vaccine (Equip (R) WNV) against intrathecal challenge of horses with a recent isolate of lineage 2 WNV. Twenty horses, sero-negative for WNV, were enrolled and were randomly allocated to one of two treatment groups: an unvaccinated control group (T01, n = 10) and a group administered with Equip (R) WNV (T02, n = 10). Horses were vaccinated at Day 0 and 21 and were challenged at day 42 with WNV lineage 2, Nea Santa/Greece/2010. Personnel performing clinical observations were blinded to treatment allocation. Sixty percent of the controls had to be euthanized after challenge compared to none of the vaccinates. A significantly lower percentage of the vaccinated animals showed clinical disease (two different clinical observations present on the same day) on six different days of study and the percentage of days with clinical disease was significantly lower in the vaccinated group. A total of 80% of the non-vaccinated horses showed viremia while only one vaccinated animal was positive by virus isolation on a single occasion. Vaccinated animals started to develop antibodies against WNV lineage 2 from day 14 (2 weeks after the first vaccination) and at day 42 (the time of onset of immunity) they had all developed a strong antibody response. Histopathology scores for all unvaccinated animals ranged from mild to very severe in each of the tissues examined (cervical spinal cord, medulla and pons), whereas in vaccinated horses 8 of 10 animals had no lesions and 2 had minimal lesions in one tissue. In conclusion, Equip (R) WNV significantly reduced the number of viremic horses, the duration and severity of clinical signs of disease and mortality following challenge with lineage 2 WNV. (C) 2014 Elsevier Ltd. All rights reserved.;2014
8707; S. Gubbins, N. A. Hartemink, A. J. Wilson, V. Moulin, C. A. Vonk Noordegraaf, M. T. W. van der Sluijs, A. J. de Smit, T. Sumner, D. Klinkenberg (2012).  Scaling from challenge experiments to the field: Quantifying the impact of vaccination on the transmission of bluetongue virus serotype 8 Preventive Veterinary Medicine, 105(#issue#),  297-308;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Cattle (Bos taurus);Neonates;2;Objective (random) sampling;animal;66;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;42;21;NA;not investigated/not given/not relevant;Reverse-transcription PCR (RT-PCR);real time RT-PCR developed by CVI.;Nucleic acid;Animal blood;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;75;85;60;89;87071;vaccine;-42;-21;0;NA;not investigated/not given/not relevant; Gubbins S, et al. 2012.; S. Gubbins, N. A. Hartemink, A. J. Wilson, V. Moulin, C. A. Vonk Noordegraaf, M. T. W. van der Sluijs, A. J. de Smit, T. Sumner, D. Klinkenberg;Scaling from challenge experiments to the field: Quantifying the impact of vaccination on the transmission of bluetongue virus serotype 8;"Bluetongue (BT) is an economically important disease of ruminants caused by bluetongue virus (BTV) and transmitted by Culicoides biting midges. The most practical and effective way to protect susceptible animals against BTV is by vaccination. Data from challenge studies in calves and sheep conducted by Intervet International b.v., in particular, presence of viral RNA in the blood of challenged animals, were used to estimate vaccine efficacy. The results of the challenge studies for calves indicated that vaccination is likely to reduce the basic reproduction number (R-0) for BTV in cattle to below one (i.e. prevent major outbreaks within a holding) and that this reduction is robust to uncertainty in the model parameters. Sensitivity analysis showed that the whether or not vaccination is predicted to reduce R-0 to below one depended on the following assumptions: (i) whether ""doubtful"" results from the challenge studies are treated as negative or positive; (ii) whether or not the probability of transmission from host to vector is reduced by vaccination; and (iii) whether the extrinsic incubation period follows a realistic gamma distribution or the more commonly used exponential distribution. For sheep, all but one of the vaccinated animals were protected and, consequently, vaccination will consistently reduce R-0 in sheep to below one. Using a stochastic spatial model for the spread of BTV in Great Britain (GB), vaccination was predicted to reduce both the incidence of disease and spatial spread in simulated BTV outbreaks in GB, in both reactive vaccination strategies and when an incursion occurred into a previously vaccinated population. (C) 2012 Elsevier B.V. All rights reserved.";2012
8707; S. Gubbins, N. A. Hartemink, A. J. Wilson, V. Moulin, C. A. Vonk Noordegraaf, M. T. W. van der Sluijs, A. J. de Smit, T. Sumner, D. Klinkenberg (2012).  Scaling from challenge experiments to the field: Quantifying the impact of vaccination on the transmission of bluetongue virus serotype 8 Preventive Veterinary Medicine, 105(#issue#),  297-308;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Neonates;NA;Objective (random) sampling;animal;62;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;NA;not investigated/not given/not relevant;Reverse-transcription PCR (RT-PCR);real time RT-PCR developed by CVI.;Nucleic acid;Animal blood;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;NA;not investigated/not given/not relevant;98;100;89;90;87072;vaccine;-21;NA;0;NA;not investigated/not given/not relevant; Gubbins S, et al. 2012.; S. Gubbins, N. A. Hartemink, A. J. Wilson, V. Moulin, C. A. Vonk Noordegraaf, M. T. W. van der Sluijs, A. J. de Smit, T. Sumner, D. Klinkenberg;Scaling from challenge experiments to the field: Quantifying the impact of vaccination on the transmission of bluetongue virus serotype 8;"Bluetongue (BT) is an economically important disease of ruminants caused by bluetongue virus (BTV) and transmitted by Culicoides biting midges. The most practical and effective way to protect susceptible animals against BTV is by vaccination. Data from challenge studies in calves and sheep conducted by Intervet International b.v., in particular, presence of viral RNA in the blood of challenged animals, were used to estimate vaccine efficacy. The results of the challenge studies for calves indicated that vaccination is likely to reduce the basic reproduction number (R-0) for BTV in cattle to below one (i.e. prevent major outbreaks within a holding) and that this reduction is robust to uncertainty in the model parameters. Sensitivity analysis showed that the whether or not vaccination is predicted to reduce R-0 to below one depended on the following assumptions: (i) whether ""doubtful"" results from the challenge studies are treated as negative or positive; (ii) whether or not the probability of transmission from host to vector is reduced by vaccination; and (iii) whether the extrinsic incubation period follows a realistic gamma distribution or the more commonly used exponential distribution. For sheep, all but one of the vaccinated animals were protected and, consequently, vaccination will consistently reduce R-0 in sheep to below one. Using a stochastic spatial model for the spread of BTV in Great Britain (GB), vaccination was predicted to reduce both the incidence of disease and spatial spread in simulated BTV outbreaks in GB, in both reactive vaccination strategies and when an incursion occurred into a previously vaccinated population. (C) 2012 Elsevier B.V. All rights reserved.";2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;2;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;91;87111;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;92;87111;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;93;87111;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;6.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;94;87111;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;95;87111;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;8;1;12.5;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;96;87111;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;0.5;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;97;87111;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;98;87112;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;8;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;99;87111;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;1;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;8;1;12.5;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;100;87111;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;6.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;101;87112;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;4;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;102;87112;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;7.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;103;87112;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;8;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;104;87112;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;0.6;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;105;87112;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);8;NA;7;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;106;87112;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;8;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;107;87112;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;2;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;8;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;8;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;108;87112;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;109;87114;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;110;87114;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;111;87114;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;112;87114;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;113;87114;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;114;87115;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;8.7;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;115;87114;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;2;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;116;87115;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;5.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;117;87115;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;118;87115;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;119;87115;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;8;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;120;87115;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;1;16.6666666666667;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;121;87115;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;1;16.6666666666667;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;122;87115;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;5;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;123;87115;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;1;16.6666666666667;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;124;87114;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;1;16.6666666666667;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;125;87114;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;4;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;126;87114;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;127;87116;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;128;87116;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;129;87116;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;2;33.3333333333333;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;130;87116;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;6;100;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;131;87116;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;132;87116;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;133;87116;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;25.8;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;134;87116;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;6;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;8.3;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;135;87116;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;136;87117;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;137;87117;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;138;87117;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;2;33.3333333333333;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;139;87117;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;2;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;140;87117;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;6;100;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;141;87117;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;142;87117;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;56;Clinical score;0;0;3;NA;not investigated/not given/not relevant;NA;NA;NA;143;87117;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;7;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;36;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;144;87117;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;145;87118;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;146;87118;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;147;87118;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;2;33.3333333333333;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;148;87118;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;149;87118;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;6;100;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;150;87118;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;4.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;151;87118;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;8;NA;44.5;Clinical score;0;0;4;NA;not investigated/not given/not relevant;NA;NA;NA;152;87118;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;8;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Adult;24;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.25;log10 TCID50;21;21;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;5.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;153;87118;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;NA;0;1st vaccination day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;154;87113;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;NA;21;Challenge day;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;155;87113;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;NA;27;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;1.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;156;87113;vaccine;-21;NA;0;6;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;NA;33;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;7.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;157;87113;vaccine;-21;NA;0;12;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;NA;35;After challenge;Clinical evaluation;"Clinical signs observed from 3 to 14 days post challenge (day 21 to 35) . Fever score: 1 point for each day of temperature >40 to 41 C; 5 points per day of temperature >41 C.  Anorexia score: 1 point per day, up to 5 days. On the fifth day the animal would be euthanized to prevent suffering. Facial lesions: conjunctivitis, hyperaemia and oedema each scored 02 points per day, depending on severity  ulcers scored 03 depending on severity. Feet lesions: lameness and coronitis each scored 02 depending on severity. Respiratory tract lesions: rhinitis, coughing and dyspnoea, each scored 02 depending on severity. Veterinary intervention: 20 points independent of the number of interventions. These points were not taken in account if the animal had to be euthanized.  Death (natural or euthanasia): 40 points.";not investigated/not given/not relevant;live animal - clinical observation;6;NA;4.8;Clinical score;0;0;0;NA;not investigated/not given/not relevant;NA;NA;NA;158;87113;vaccine;-21;NA;0;14;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;NA;42;After challenge;Seroneutralisation test;SNT developed at MSD animal health;Antibody;Blood serum (as part-nature);6;NA;6.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;159;87113;vaccine;-21;NA;0;21;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;21;Challenge day;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;160;87113;vaccine;-21;NA;0;0;Challenge day; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;23;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;6;100;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;161;87113;vaccine;-21;NA;0;2;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8711; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit (2012).  Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine Vaccine, 30(#issue#),  2228-2235;3;Netherlands;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Sheep (Ovis aries);Young;12;Objective (random) sampling;animal;6;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;7.3;log10 TCID50;21;21;25;After challenge;Real-Time PCR (qualitative or quantitative);pan-BTV real-time RT-PCR targeting genome segment 1 (VP1 gene);Nucleic acid;Animal blood;6;6;100;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;162;87113;vaccine;-21;NA;0;4;After challenge; Veronique Moulin, et al. 2012.; Veronique Moulin, Cor Vonk Noordegraaf, Birgit Makoschey, Mirjam van der Sluijs, Eva Veronesi, Karin Darpel, Peter P. C. Mertens, Hans de Smit;Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine;The ability to reduce clinical signs, induce neutralizing antibodies, and perhaps most importantly, to prevent or reduce viraemia (and therefore virus-transmission), represent primary criteria for assessment of bluetongue virus (BTV) vaccine efficacy. Identification of BTV challenge-strains that reliably induce viraemia and clinical signs comparable to those in naturally infected animals, is therefore important for vaccine evaluation. Texel cross-breed and Dorset Poll sheep vaccinated with inactivated BTV-8 vaccine ('Bovilis (R) BTV8' from MSD Animal Health), were challenged with low-passage BTV-8 (Northern European strain) grown in either insect (Culicoides) or mammalian cell-cultures. The severity of clinical signs was recorded (using a modified numerical scoring-system, which is described) along with viraemia and serum neutralizing (SN) antibody levels. Low level SN-antibodies were detected at the time of challenge (three weeks after vaccination). All unvaccinated control animals became infected after challenge, developing high SN-antibody titres by 21 days post challenge (dpc). Vaccinees showed faster increases in SN-antibody titres ('booster' response), with significantly higher titres at 6 dpc than unvaccinated controls. Although only limited clinical-signs could be attributed to BTV in younger animals infected with the mammalian-cell-culture derived virus, both BTV-8 challenge preparations induced severe clinical signs comparable to 'bluetongue' observed during natural outbreaks in older unvaccinated animals. Challenge with BTV-8 grown in Culicoides cell-cultures seemed to induce greater severity of clinical-scores and 'post-mortem lesions' than the mammalian-derived BTV-8 strain. Vaccination reduced clinical signs, fever, and viraemia equally well after challenge with either virus preparation. (C) 2011 Elsevier Ltd. All rights reserved.;2012
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;-3;Not vaccinated/Before vaccination;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;0;0;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;163;87421;vaccine;-49;-21;0;-52;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;21;Between vaccination doses;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;0.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;164;87421;vaccine;-49;-21;0;-28;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;1.6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;165;87421;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;-3;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;107.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;166;87421;vaccine;-49;-21;0;-52;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;2.6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;167;87421;vaccine;-49;-21;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;15;Between vaccination doses;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;6;36.5;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;168;87421;vaccine;-49;-21;0;-34;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;10;Between vaccination doses;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;6;35.5;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;169;87421;vaccine;-49;-21;0;-39;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;28;2nd vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;9;22.7;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;170;87421;vaccine;-49;-21;0;-21;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;21;Between vaccination doses;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;5;34.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;171;87421;vaccine;-49;-21;0;-28;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;42;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;10;5.5;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;172;87421;vaccine;-49;-21;0;-7;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;33;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;9;13;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;173;87421;vaccine;-49;-21;0;-16;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;38;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;10;5.7;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;174;87421;vaccine;-49;-21;0;-11;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;10;5.7;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;175;87421;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;56;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;9;8.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;176;87421;vaccine;-49;-21;0;7;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;63;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;9;6.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;177;87421;vaccine;-49;-21;0;14;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;9;5.4;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;178;87421;vaccine;-49;-21;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;179;87422;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;53;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;1;39.5;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;180;87421;vaccine;-49;-21;0;4;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;51;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;6;36.9;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;181;87421;vaccine;-49;-21;0;2;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;60;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;182;87421;vaccine;-49;-21;0;11;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;56;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;183;87421;vaccine;-49;-21;0;7;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;63;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;184;87421;vaccine;-49;-21;0;14;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;65;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;185;87421;vaccine;-49;-21;0;16;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;186;87421;vaccine;-49;-21;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;70;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;187;87421;vaccine;-49;-21;0;21;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;21;Between vaccination doses;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;0.75;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;188;87422;vaccine;-49;-21;0;-28;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;-3;Not vaccinated/Before vaccination;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;0;0;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;189;87422;vaccine;-49;-21;0;-52;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;2.1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;190;87422;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;3;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;191;87422;vaccine;-49;-21;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;10;Between vaccination doses;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;5;40.9;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;192;87422;vaccine;-49;-21;0;-39;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;-3;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;107;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;193;87422;vaccine;-49;-21;0;-52;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;15;Between vaccination doses;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;6;34.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;194;87422;vaccine;-49;-21;0;-34;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;21;Between vaccination doses;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;8;29.3;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;195;87422;vaccine;-49;-21;0;-28;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;33;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;9;12.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;196;87422;vaccine;-49;-21;0;-16;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;28;2nd vaccination day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;3;34.4;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;197;87422;vaccine;-49;-21;0;-21;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;38;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);9;9;5.4;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;198;87422;vaccine;-49;-21;0;-11;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;42;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);8;8;5.9;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;199;87422;vaccine;-49;-21;0;-7;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);8;8;5.6;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;200;87422;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;56;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);8;8;7.8;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;201;87422;vaccine;-49;-21;0;7;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;63;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);8;8;7.1;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;202;87422;vaccine;-49;-21;0;14;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);8;8;5;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;203;87422;vaccine;-49;-21;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;51;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;2;38.5;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;204;87422;vaccine;-49;-21;0;2;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;56;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;205;87422;vaccine;-49;-21;0;7;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;53;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;206;87422;vaccine;-49;-21;0;4;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;63;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;207;87422;vaccine;-49;-21;0;14;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;60;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;208;87422;vaccine;-49;-21;0;11;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;70;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;209;87422;vaccine;-49;-21;0;21;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;65;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;210;87422;vaccine;-49;-21;0;16;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;211;87422;vaccine;-49;-21;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;2;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;8;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;212;87422;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;1;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;28;1;millilitre;0;28;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;9;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;213;87421;vaccine;-49;-21;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;-3;Not vaccinated/Before vaccination;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;0;0;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;214;87423;control;NA;NA;0;-52;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;21;Between vaccination doses;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;0;0;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;215;87423;control;NA;NA;0;-28;Vaccinated, not challenged; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;0;0;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;216;87423;control;NA;NA;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;Seroneutralisation test;The neutralising titer of each serum was defined as the highest dilution allowing neuralisation of the 100 TCID50;Antibody;Blood serum (as part-nature);10;NA;3;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;217;87423;control;NA;NA;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;-3;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;107.5;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;218;87423;control;NA;NA;0;-52;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;10;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;100.1;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;219;87423;control;NA;NA;0;-39;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;15;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;104.4;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;220;87423;control;NA;NA;0;-34;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;21;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;95.7;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;221;87423;control;NA;NA;0;-28;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;28;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;100;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;222;87423;control;NA;NA;0;-21;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;33;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;99.3;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;223;87423;control;NA;NA;0;-16;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;38;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;102.2;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;224;87423;control;NA;NA;0;-11;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;42;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;103.6;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;225;87423;control;NA;NA;0;-7;Not vaccinated/Before vaccination; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;0;100.1;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;226;87423;control;NA;NA;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;56;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;6;41.3;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;227;87423;control;NA;NA;0;7;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;63;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;9;17.2;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;228;87423;control;NA;NA;0;14;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;ELISA, Competitive ELISA (C-ELISA);cELISA ID-screen bluetongue competition kit, ID VET, France, IP<35 is considered positive;Antibody;Blood serum (as part-nature);10;10;8.1;IP;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;229;87423;control;NA;NA;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;49;Challenge day;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;0;40;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;230;87423;control;NA;NA;0;0;Challenge day; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;51;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;6;36.6;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;231;87423;control;NA;NA;0;2;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;53;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;28.9;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;232;87423;control;NA;NA;0;4;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;56;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;24.1;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;233;87423;control;NA;NA;0;7;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;60;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;23.6;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;234;87423;control;NA;NA;0;11;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;63;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;24.1;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;235;87423;control;NA;NA;0;14;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;65;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;25.6;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;236;87423;control;NA;NA;0;16;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;70;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;27.8;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;237;87423;control;NA;NA;0;21;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
8742; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara (2011).  Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Vaccine, 29(#issue#),  2495-2502;3;France;not investigated/not given/not relevant;2010;Bluetongue virus;not investigated/not given/not relevant;BTV-8;Goat (Capra aegagrus hircus);Young;4;Objective (random) sampling;animal;10;SUBCUTANEOUS;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;not investigated/not given/not relevant;not investigated/not given/not relevant;4.68;log10 TCID50;49;21;77;After challenge;Reverse-transcription PCR (RT-PCR);ADIAVET BTV Realtime A381 targeting a BTV-8 specific sequence of the VP2 gene;Nucleic acid;Animal blood;10;10;28.7;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;238;87423;control;NA;NA;0;28;After challenge; Breard E, et al. 2011.; E. Breard, G. Belbis, C. Hamers, V. Moulin, T. Lilin, F. Moreau, Y. Millemann, C. Montange, C. Sailleau, B. Durand, A. Desprat, C. Viarouge, B. Hoffmann, H. de Smit, S. Goutebroze, P. Hudelet, S. Zientara;Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats;Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP (R) 8 (MERIAL) and BOVILIS (R) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines. (C) 2011 Elsevier Ltd. All rights reserved.;2011
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;21;Challenge day;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;239;501093;control;NA;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Foetus / stillbirth / neonatus (as part-nature);18;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;240;501091;vaccine;-21;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Placenta (as part-nature);10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;241;501091;vaccine;-21;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;1;10;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;242;501091;vaccine;-21;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;21;Challenge day;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;243;501091;vaccine;-21;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;0;1st vaccination day;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;244;501091;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Foetus / stillbirth / neonatus (as part-nature);8;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;245;501093;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;0;Not vaccinated/Before vaccination;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;246;501096;control;NA;NA;0;-42;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;21;Not vaccinated/Before vaccination;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;247;501096;control;NA;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;248;501096;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;66;After challenge;Virus Isolation (VI);targeting VP1 gene;Virus;Placenta (as part-nature);4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;249;501096;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;66;After challenge;Virus Isolation (VI);targeting VP1 gene;Virus;Foetus / stillbirth / neonatus (as part-nature);4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;250;501096;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;0;Not vaccinated/Before vaccination;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;251;501093;control;NA;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Placenta (as part-nature);4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;252;501093;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;Uninfected Vero cell culture;10;milliliter;21;NA;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;4;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;253;501093;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Foetus / stillbirth / neonatus (as part-nature);10;2;20;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;254;501095;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Placenta (as part-nature);10;4;40;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;255;501095;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;10;100;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;256;501095;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;21;Not vaccinated/Before vaccination;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;257;501095;control;NA;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;0;Not vaccinated/Before vaccination;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;258;501095;control;NA;NA;0;-42;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Foetus / stillbirth / neonatus (as part-nature);23;11;47.8260869565217;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;259;501092;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Placenta (as part-nature);9;7;77.7777777777778;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;260;501092;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;21;Challenge day;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;261;501092;control;NA;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;45;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;6;60;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;262;501092;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;0;Not vaccinated/Before vaccination;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;263;501092;control;NA;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;0;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;264;501092;control;NA;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;42;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;265;501092;control;NA;NA;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;0;1st vaccination day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;266;501091;vaccine;-21;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;21;Challenge day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;267;501091;vaccine;-21;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;42;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;268;501091;vaccine;-21;NA;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;1;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;21;45;After challenge;Real-Time PCR (qualitative or quantitative);Targeting  VP1 gene;Nucleic acid;Animal blood;10;1;29.99;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;269;501091;vaccine;-21;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;66;After challenge;Real-Time PCR (qualitative or quantitative);targeting VP1 gene;Nucleic acid;Animal blood;4;0;29.99;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;270;501096;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;0;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);4;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;271;501096;control;NA;NA;0;-42;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;42;Challenge day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);4;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;272;501096;control;NA;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;45;After challenge;Real-Time PCR (qualitative or quantitative);Targeting VP1 gene;Nucleic acid;Animal blood;4;0;29.99;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;273;501093;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;6;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;42;NA;63;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);4;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;274;501096;control;NA;NA;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;0;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;275;501093;control;NA;NA;0;-21;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;42;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;276;501093;control;NA;NA;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;3;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;4;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with a placebo;Uninfected Vero cell culture;10;milliliter;21;NA;21;Challenge day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;277;501093;control;NA;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;63;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;278;501095;control;NA;NA;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;42;Challenge day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;279;501095;control;NA;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;0;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;280;501095;control;NA;NA;0;-42;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;5;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;NA;66;After challenge;Real-Time PCR (qualitative or quantitative);Targeting VP1 gene;Nucleic acid;Animal blood;10;10;29.99;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;281;501095;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;21;Challenge day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;282;501092;control;NA;NA;0;0;Challenge day; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;2;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;21;NA;45;After challenge;Real-Time PCR (qualitative or quantitative);Targeting VP1 gene;Nucleic acid;Animal blood;10;6;29.99;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;283;501092;control;NA;NA;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;42;2nd vaccination day;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;284;501094;vaccine;-42;-21;0;0;Vaccinated, not challenged; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Foetus / stillbirth / neonatus (as part-nature);10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;285;501094;vaccine;-42;-21;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;286;501094;vaccine;-42;-21;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;66;After challenge;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Placenta (as part-nature);10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;287;501094;vaccine;-42;-21;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;0;1st vaccination day;Virus Isolation (VI);not investigated/not given/not relevant;Virus;Animal blood;10;0;0;% POS, Virus Isolation (VI);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;288;501094;vaccine;-42;-21;0;-42;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;42;2nd vaccination day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;289;501094;vaccine;-42;-21;0;0;Vaccinated, not challenged; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;0;1st vaccination day;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;290;501094;vaccine;-42;-21;0;-42;Not vaccinated/Before vaccination; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;63;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;291;501094;vaccine;-42;-21;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;21;66;After challenge;Real-Time PCR (qualitative or quantitative);Targeting VP1 gene;Nucleic acid;Animal blood;10;0;29.99;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;292;501094;vaccine;-42;-21;0;24;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50109; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit (2012).  Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers Vaccine, 30(3),  647;4;Netherlands;Unknown;2010;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;8;not investigated/not given/not relevant;animal;10;SUBCUTANEOUS;Bovilis BTV8;2;21;1;millilitre;0;21;Challenged with the VBD-pathogen;OvBTV-8Ver1291007 07K07;10;milliliter;42;42;63;After challenge;ELISA, Competitive ELISA (C-ELISA);VMRD;Antibody;Blood serum (as part-nature);10;10;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;293;501094;vaccine;-42;-21;0;21;After challenge; van der Sluijs MTW, et al. 2012.; M.T.W. van der Sluijs, D.P.H. Schroer-Joosten, A. Fid-Fourkour, M.P. Vrijenhoek, I. Debyser, D.A. Gregg, D.M. Dufe, V. Moulin, R.J.M. Moormann, A.J. de Smit;Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers;The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative.Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well.Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.  2011 Elsevier Ltd.;2012
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;7;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;294;501467;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;7;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;295;501467;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;20;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;3;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Vaccinated, not challenged;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;3;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;296;5014620;vaccine;-365;NA;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;19;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Vaccinated, not challenged;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;297;5014619;vaccine;-365;NA;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;13;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;5;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;298;5014613;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;22;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Not vaccinated/Before vaccination;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;299;5014622;control;NA;NA;0;0;Not vaccinated/Before vaccination; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;22;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;300;5014622;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;21;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;4;80;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;301;5014621;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;21;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;302;5014621;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;20;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;3;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);3;3;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;303;5014620;vaccine;-365;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;19;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;2;40;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;304;5014619;vaccine;-365;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;18;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;305;5014618;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;18;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;306;5014618;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;17;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;307;5014617;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;17;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;308;5014617;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;16;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;5;83.3333333333333;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;309;5014616;vaccine;-365;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;16;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;310;5014616;vaccine;-365;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;15;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;311;5014615;vaccine;-365;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;15;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;312;5014615;vaccine;-365;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;14;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;313;5014614;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;14;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;314;5014614;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;22;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;5;83.3333333333333;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;315;5014622;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;22;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;316;5014622;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;21;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;317;5014621;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;21;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;5;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;318;5014621;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;20;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;3;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);3;3;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;319;5014620;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;20;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;3;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;3;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;320;5014620;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;19;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;5;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;321;5014619;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;19;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;322;5014619;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;18;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;5;83.3333333333333;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;323;5014618;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;18;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;324;5014618;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;17;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Ovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;325;5014617;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;17;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Ovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;326;5014617;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;16;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;327;5014616;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;16;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;1;16.6666666666667;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;328;5014616;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;15;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;329;5014615;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;15;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;330;5014615;vaccine;-365;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;14;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;6;100;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;331;5014614;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;14;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;332;5014614;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;13;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;333;5014613;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;13;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;334;5014613;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;13;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;335;5014613;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;12;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;5;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;336;5014612;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;12;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;3;60;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;337;5014612;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;12;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;338;5014612;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;12;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;339;5014612;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;11;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;4;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);4;4;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;340;5014611;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;11;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;341;5014611;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;11;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);5;1;20;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;342;5014611;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;11;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;5;1;20;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;343;5014611;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;10;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;5;83.3333333333333;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;344;5014610;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;10;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;345;5014610;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;10;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;346;5014610;control;NA;NA;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;10;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2 gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;347;5014610;control;NA;NA;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;9;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;348;501469;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;9;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;5;83.3333333333333;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;349;501469;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;9;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;350;501469;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;9;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;351;501469;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;8;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;352;501468;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;8;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;353;501468;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;8;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 VP2gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;354;501468;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;8;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 VP2gene;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;355;501468;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;7;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;28;After challenge;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;356;501467;vaccine;-386;-365;0;28;After challenge; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;7;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Challenged with the VBD-pathogen;BTV-8 strain from Germany isolated in 2007;4;milliliter;0;NA;0;Challenge day;ELISA, Competitive ELISA (C-ELISA);cut-off 50%;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;357;501467;vaccine;-386;-365;0;0;Challenge day; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;1;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;220;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;2;21;NA;not investigated/not given/not relevant;-386;-365;Not challenged;not investigated/not given/not relevant;NA;not investigated/not given/not relevant;0;NA;0;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);VMRD, 50% cutoff value;Antibody;Blood serum (as part-nature);220;216;98.1818181818182;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;358;501461;vaccine;-386;-365;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;2;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;221;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;2;21;NA;not investigated/not given/not relevant;-386;-365;Not challenged;not investigated/not given/not relevant;NA;not investigated/not given/not relevant;0;NA;0;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);VMRD, 50% cutoff value;Antibody;Blood serum (as part-nature);221;214;96.8325791855204;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;359;501462;vaccine;-386;-365;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;3;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Cattle (Bos taurus);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;182;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Not challenged;not investigated/not given/not relevant;NA;not investigated/not given/not relevant;0;NA;0;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);VMRD, 50% cutoff value;Antibody;Blood serum (as part-nature);182;175;96.1538461538462;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;360;501463;vaccine;-386;-365;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;4;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;55;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;NA;not investigated/not given/not relevant;-365;NA;Not challenged;not investigated/not given/not relevant;NA;not investigated/not given/not relevant;0;NA;0;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);VMRD, 50% cutoff value;Antibody;Blood serum (as part-nature);55;47;85.4545454545455;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;361;501464;vaccine;-365;NA;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;5;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;98;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;NA;not investigated/not given/not relevant;-365;NA;Not challenged;not investigated/not given/not relevant;NA;not investigated/not given/not relevant;0;NA;0;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);VMRD, 50% cutoff value;Antibody;Blood serum (as part-nature);98;92;93.8775510204082;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;362;501465;vaccine;-365;NA;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50146; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer (2010).  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle Vaccine, 28(27),  4348;6;Germany;Unknown;2009;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;70;SUBCUTANEOUS;Zulvac 8 Bovis;2;21;NA;not investigated/not given/not relevant;-386;-365;Not challenged;not investigated/not given/not relevant;NA;not investigated/not given/not relevant;0;NA;0;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);VMRD, 50% cutoff value;Antibody;Blood serum (as part-nature);70;70;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;363;501466;vaccine;-386;-365;0;0;Vaccinated, not challenged; Wckerlin R, et al. 2010.; R. Wckerlin, M. Eschbaumer, P. Knig, B. Hoffmann, M. Beer;Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle;The long-term efficacy of three commercially available inactivated vaccines against bluetongue virus serotype 8 (BTV-8) (BLUEVAC 8, Zulvac 8, and BTVPUR AlSap 8) was evaluated in a seroprevalence study and challenge experiments. Seroprevalences 1 year after vaccination ranged from 75% to 100%. In two infection experiments, groups of vaccinated sheep and cattle selected either randomly or for low antibody levels were challenged with a European BTV-8 strain 12 months after vaccination. With two exceptions, all animals, including those with low antibody levels prior to challenge, were protected from viral replication and clinical disease even at low initial antibody levels. Vaccination of susceptible ruminants in yearly intervals is thus considered an adequate scheme for BTV-8 control in Europe.  2010 Elsevier Ltd. All rights reserved.;2010
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;299;Not vaccinated/Before vaccination;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);3;0;0;% POS, Seroneutralisation test;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;364;501602;control;NA;NA;0;-1;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;304;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);3;0;0;% POS, Seroneutralisation test;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;365;501602;control;NA;NA;0;4;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;321;After challenge;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;7;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;366;501601;vaccine;-300;NA;0;21;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;308;After challenge;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;7;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;367;501601;vaccine;-300;NA;0;8;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;306;After challenge;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;7;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;368;501601;vaccine;-300;NA;0;6;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;304;After challenge;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;6;85.7142857142857;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;369;501601;vaccine;-300;NA;0;4;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;299;Vaccinated, not challenged;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;6;85.7142857142857;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;370;501601;vaccine;-300;NA;0;-1;Vaccinated, not challenged; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;321;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;7;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;371;501601;vaccine;-300;NA;0;21;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;308;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;7;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;372;501601;vaccine;-300;NA;0;8;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;306;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;7;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;373;501601;vaccine;-300;NA;0;6;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;304;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;4;57.1428571428571;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;374;501601;vaccine;-300;NA;0;4;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;321;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);7;7;2.8;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;375;501601;vaccine;-300;NA;0;21;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;299;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);7;3;42.8571428571429;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;376;501601;vaccine;-300;NA;0;-1;Vaccinated, not challenged; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;308;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);7;7;2.6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;377;501601;vaccine;-300;NA;0;8;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;306;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);7;7;2.2;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;378;501601;vaccine;-300;NA;0;6;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Bovilis BTV8;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;304;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);7;7;1.9;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;379;501601;vaccine;-300;NA;0;4;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;1;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;7;SUBCUTANEOUS;Unvaccinated control;1;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;300;299;Vaccinated, not challenged;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);7;6;1.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;380;501601;control;-300;NA;0;-1;Vaccinated, not challenged; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;304;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;0;0;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;381;501602;control;NA;NA;0;4;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;299;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;0;0;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;382;501602;control;NA;NA;0;-1;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;321;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;3;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;383;501602;control;NA;NA;0;21;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;308;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;3;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;384;501602;control;NA;NA;0;8;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;306;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;385;501602;control;NA;NA;0;6;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;299;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;386;501602;control;NA;NA;0;-1;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;304;After challenge;ELISA, Competitive ELISA (C-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;387;501602;control;NA;NA;0;4;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;321;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;3;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;388;501602;control;NA;NA;0;21;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;306;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;3;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;389;501602;control;NA;NA;0;6;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;308;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);not investigated/not given/not relevant;Antibody;Blood serum (as part-nature);3;3;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;390;501602;control;NA;NA;0;8;Not vaccinated/Before vaccination; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;321;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);3;3;2.5;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;391;501602;control;NA;NA;0;21;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;308;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);3;3;1.6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;392;501602;control;NA;NA;0;8;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50160; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten (2009).  Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep Vaccine, 27(52),  7326;2;United Kingdom;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;7.5;not investigated/not given/not relevant;animal;3;not investigated/not given/not relevant;Unvaccinated control;NA;NA;NA;not investigated/not given/not relevant;NA;NA;Challenged with the VBD-pathogen;BTV-8 Netherlands 2006 strain in KC cells (NET2006/02);1;milliliter;300;NA;306;After challenge;Seroneutralisation test;Neutralization titre was determined as the dilution of serum giving 50% neutralisation end point SNT antibody titres were expressed as log10 reciprocal of the highest positive serum dilution.;Antibody;Blood serum (as part-nature);3;1;1;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;393;501602;control;NA;NA;0;6;After challenge; Oura CAL, et al. 2009.; C.A.L. Oura, J.L.N. Wood, A.J. Sanders, A. Bin-Tarif, M. Henstock, L. Edwards, T. Floyd, H. Simmons, C.A. Batten;Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep;Bluetongue virus serotype 8 (BTV-8) has caused a major outbreak of disease in cattle and sheep in several countries across northern and western Europe from 2006 to 2008. In 2008 the European Union instigated a mass-vaccination programme in affected countries using whole virus inactivated vaccines. We evaluated vaccinal responses in sheep and the ability of the vaccine to protect against experimental challenge. Sheep vaccinated 10 months previously under field conditions were challenged with BTV-8. One of 7 vaccinated sheep became infected, as evidenced by detection of viral RNA by real-time RT-PCR and by virus isolation. The remaining 6 sheep appeared fully protected from virus replication. None of the vaccinated sheep showed clinical signs of BTV and there was a good correlation between the presence of neutralising antibodies on challenge and protection. Commercially available ELISAs were evaluated for their ability to detect antibodies in sheep vaccinated on a single occasion. The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;4;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;6;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Placebo;NA;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;97;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;4;2;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;394;501684;control;-90;NA;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;4;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;6;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Placebo;NA;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;104;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;88;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;395;501684;control;-90;NA;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;4;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;6;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Placebo;NA;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;111;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;118;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;396;501684;control;-90;NA;0;21;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;4;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;6;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Placebo;NA;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;-1;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);double antigen sandwich assay (Ingezim BTV DR);Antibody;Blood serum (as part-nature);6;0;0;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;397;501684;control;-90;NA;0;-91;Not vaccinated/Before vaccination; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;4;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;6;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Placebo;NA;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;-1;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);ID screen Bluetongue competition, ID VET;Antibody;Blood serum (as part-nature);6;0;0;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;398;501684;control;-90;NA;0;-91;Not vaccinated/Before vaccination; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;4;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;6;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;Placebo;NA;NA;NA;not investigated/not given/not relevant;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;90;Challenge day;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;0;0;% POS, Seroneutralisation test;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;399;501684;control;-90;NA;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;111;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;400;501683;vaccine;-90;NA;0;21;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;107;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;401;501683;vaccine;-90;NA;0;17;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;104;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;402;501683;vaccine;-90;NA;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;102;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;403;501683;vaccine;-90;NA;0;12;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;97;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;404;501683;vaccine;-90;NA;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;96;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;405;501683;vaccine;-90;NA;0;6;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;95;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;406;501683;vaccine;-90;NA;0;5;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;94;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;407;501683;vaccine;-90;NA;0;4;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;93;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;408;501683;vaccine;-90;NA;0;3;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;100;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;409;501683;vaccine;-90;NA;0;10;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;90;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;410;501683;vaccine;-90;NA;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;111;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;411;501682;vaccine;-90;-69;0;21;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;107;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;412;501682;vaccine;-90;-69;0;17;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;104;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;413;501682;vaccine;-90;-69;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;100;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;414;501682;vaccine;-90;-69;0;10;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;102;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;415;501682;vaccine;-90;-69;0;12;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;97;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;416;501682;vaccine;-90;-69;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;95;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;417;501682;vaccine;-90;-69;0;5;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;96;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;418;501682;vaccine;-90;-69;0;6;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;94;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;419;501682;vaccine;-90;-69;0;4;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;93;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;420;501682;vaccine;-90;-69;0;3;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;90;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;5;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;421;501682;vaccine;-90;-69;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;90;Challenge day;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;0;0;% POS, Real-Time PCR (qualitative or quantitative);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;422;501681;vaccine;-90;NA;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;97;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;313.3;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;423;501683;vaccine;-90;NA;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;104;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;420;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;424;501683;vaccine;-90;NA;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;111;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;493.3;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;425;501683;vaccine;-90;NA;0;21;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;90;Challenge day;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;5;8.4;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;426;501683;vaccine;-90;NA;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;-1;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);double antigen sandwich assay (Ingezim BTV DR);Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;427;501683;vaccine;-90;NA;0;-91;Not vaccinated/Before vaccination; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;3;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-BTVPUR Alsap 8;1;NA;1;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;-1;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);ID screen Bluetongue competition, ID VET;Antibody;Blood serum (as part-nature);6;6;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;428;501683;vaccine;-90;NA;0;-91;Not vaccinated/Before vaccination; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;-1;Not vaccinated/Before vaccination;ELISA, Competitive ELISA (C-ELISA);ID screen Bluetongue competition, ID VET;Antibody;Blood serum (as part-nature);5;5;100;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;429;501682;vaccine;-90;-69;0;-91;Not vaccinated/Before vaccination; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;-1;Not vaccinated/Before vaccination;Indirect ELISA (I-ELISA);double antigen sandwich assay (Ingezim BTV DR);Antibody;Blood serum (as part-nature);5;5;100;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;430;501682;vaccine;-90;-69;0;-91;Not vaccinated/Before vaccination; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;97;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;5;240;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;431;501681;vaccine;-90;NA;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;111;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;560;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;432;501681;vaccine;-90;NA;0;21;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;104;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;6;446.6;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;433;501681;vaccine;-90;NA;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;90;Challenge day;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);6;5;3.8;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;434;501681;vaccine;-90;NA;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;-1;Vaccinated, not challenged;Indirect ELISA (I-ELISA);double antigen sandwich assay (Ingezim BTV DR);Antibody;Blood serum (as part-nature);6;5;83.3333333333333;% POS, Indirect ELISA (I-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;435;501681;vaccine;-90;NA;0;-91;Vaccinated, not challenged; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;-1;Vaccinated, not challenged;ELISA, Competitive ELISA (C-ELISA);ID screen Bluetongue competition, ID VET;Antibody;Blood serum (as part-nature);6;5;83.3333333333333;% POS, ELISA, Competitive ELISA (C-ELISA);NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;436;501681;vaccine;-90;NA;0;-91;Vaccinated, not challenged; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;97;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);5;5;160;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;437;501682;vaccine;-90;-69;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;90;Challenge day;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);5;5;30.4;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;438;501682;vaccine;-90;-69;0;0;Challenge day; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;104;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);5;5;768;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;439;501682;vaccine;-90;-69;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;2;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;5;SUBCUTANEOUS;SBV-Zulvac SBV;2;21;2;millilitre;0;21;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;63;111;After challenge;Seroneutralisation test;Neutralising doses given samples (ND50) are the reciprocal of the serum dilution that caused virus neutralisation in 50% of the replicates tested;Antibody;Blood serum (as part-nature);5;5;556;titer;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;440;501682;vaccine;-90;-69;0;21;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;100;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;2;30.09;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;441;501681;vaccine;-90;NA;0;10;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;1011;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;29.46;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;442;501681;vaccine;-90;NA;0;921;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;107;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;27.24;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;443;501681;vaccine;-90;NA;0;17;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;104;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;29.39;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;444;501681;vaccine;-90;NA;0;14;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;102;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;27.5;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;445;501681;vaccine;-90;NA;0;12;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;97;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;22.47;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;446;501681;vaccine;-90;NA;0;7;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;96;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;21.49;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;447;501681;vaccine;-90;NA;0;6;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;94;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;27.58;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;448;501681;vaccine;-90;NA;0;4;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;95;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;24.35;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;449;501681;vaccine;-90;NA;0;5;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
50168; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer (2009).  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep Vaccine, 27(31),  4169;1;Germany;Unknown;2008;Bluetongue virus;serotype;BTV-8;Sheep (Ovis aries);not investigated/not given/not relevant;NA;not investigated/not given/not relevant;animal;6;SUBCUTANEOUS;BTV-Bluevac BTV8 - Inactivate virus vaccine;1;NA;2;millilitre;0;NA;Challenged with the VBD-pathogen;Isolated BTV from an outbreak;4;milliliter;90;90;93;After challenge;Real-Time PCR (qualitative or quantitative);BTV-8 outer shell protein VP2;Nucleic acid;Animal blood;6;1;32.17;Cq/Ct;NA;NA;NA;NA;not investigated/not given/not relevant;NA;NA;NA;450;501681;vaccine;-90;NA;0;3;After challenge; Eschbaumer M, et al. 2009.; M. Eschbaumer, B. Hoffmann, P. Knig, J.P. Teifke, J.M. Gethmann, F.J. Conraths, C. Probst, T.C. Mettenleiter, M. Beer;Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep;Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.  2009 Elsevier Ltd. All rights reserved.;2009
